Iovance Biotherapeutics and GT Biopharma: Pioneering Advances in Cancer Immunotherapy Trials

Innovative Advances in Cancer Immunotherapy: GT Biopharma's GTB-3650 Trial Progresses

GT Biopharma, Inc., a clinical-stage immunotherapy company based in San Francisco, is making notable strides in cancer treatment with its Phase 1 trial of GTB-3650. This innovative therapy targets relapsed or refractory CD33-expressing blood cancers, such as acute myeloid leukemia (AML) and high-risk myelodysplastic syndrome (MDS). The oncology landscape is currently experiencing a rapid evolution, with eight new drug approvals occurring between July and September 2025. This surge is largely attributed to advancements in cellular immunotherapy, notably CAR-NK and CAR-Treg therapies, which are effectively addressing historical manufacturing challenges and transitioning treatments to outpatient settings.

The GTB-3650 trial is particularly promising, as it has commenced treatment for Cohort 3 patients without any dose-limiting toxicities or safety concerns reported thus far. This trial employs a continuous infusion model, allowing for alternating cycles of treatment over a maximum duration of four months, contingent upon patient response. These innovative approaches enhance the potential for successful outcomes in patients who have limited treatment options. As GT Biopharma prepares to advance to Cohort 4 by the end of 2025, the medical community eagerly anticipates further updates, which are expected in early 2026.

Early blood test results from the trial indicate a significant increase in the activation of natural killer (NK) cells, a key component of the immune response that could markedly enhance treatment efficacy. This activation is crucial in the battle against challenging cancer types, offering hope to patients who have previously faced limited therapeutic options. GT Biopharma's focus on harnessing the power of the immune system through its advanced therapies may redefine traditional approaches to cancer treatment, ultimately increasing access to innovative therapies for a broader patient population.

In the larger context, the global cancer immunotherapy market is projected to reach $370 billion by 2033, expanding at a compound annual growth rate (CAGR) of 17.5%. The robust pipeline of CAR T-cell therapies, particularly those targeting both blood cancers and solid tumors, is driving this growth. The increasing adoption of checkpoint inhibitors further supports this expanding market, underscoring the critical role of immunotherapy in the future of cancer treatment.

GT Biopharma's advancements in developing GTB-3650 not only highlight the company's commitment to innovation but also signal a transformative shift in how challenging cancers may be treated, paving the way for improved patient outcomes and broader access to cutting-edge therapies.